Related Experiment Video
Updated: Jun 21, 2026
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Cap in hand: targeting eIF4E
1Centre for Biomolecular Sciences and School of Pharmacy, University of Nottingham, Nottingham, UK. peter.fischer@nottingham.ac.uk
Abstract:
Recognition of the mRNA cap structure by the translation initiation factor eIF4E is central to protein synthesis in general and eIF4E activity is especially important for the production of many of the proteins that give rise to the hallmarks of cancer. Because transformed cells have a heightened requirement for the expression of prosurvival factors, targeting translation appears to be an attractive anticancer strategy and proof-of-concept studies in which oncogenic eIF4E function is suppressed in various different ways show that tumour cells are selectively sensitive to inhibition of protein synthesis at the level of eIF4E. The emerging understanding of the functions, regulation, and structural biology of eIF4E now makes possible the pharmacological targeting of this key translation initiation factor.
Insights
Targeting the mRNA cap-binding protein eukaryotic initiation factor 4E (eIF4E) offers a promising anticancer strategy. Inhibiting eIF4E selectively targets cancer cells by disrupting essential protein synthesis.
Area of Science:
- Molecular Biology
- Cancer Biology
- Biochemistry
Background:
- The mRNA cap structure recognition by eukaryotic initiation factor 4E (eIF4E) is crucial for protein synthesis.
- eIF4E activity is particularly vital for producing proteins associated with cancer hallmarks.
- Transformed cells exhibit increased dependency on prosurvival factors, making translation targeting an attractive anticancer approach.
Purpose of the Study:
- To explore the potential of targeting eIF4E as an anticancer strategy.
- To validate the selective sensitivity of tumor cells to eIF4E inhibition.
- To leverage emerging knowledge of eIF4E's functions, regulation, and structural biology for drug development.
Main Methods:
- Proof-of-concept studies involving suppression of oncogenic eIF4E function.
- Analysis of tumor cell sensitivity to protein synthesis inhibition at the eIF4E level.
- Integration of current understanding of eIF4E's structural biology and regulation.
Main Results:
- Suppression of eIF4E function selectively impacts tumor cells.
- Tumor cells demonstrate sensitivity to the inhibition of protein synthesis mediated by eIF4E.
- Emerging data on eIF4E functions, regulation, and structural biology support its pharmacological targeting.
Conclusions:
- Targeting eIF4E is a viable and selective anticancer strategy.
- The understanding of eIF4E's biology enables the development of novel therapeutics.
- Pharmacological targeting of eIF4E holds promise for cancer treatment.
